Please note that the table below may need to be scrolled horizontally or vertically in order to view all information, depending on your device.
| Regime | Drugs | Indications |
| ABVD |
|
Hodgkin Lymphoma |
| Azacitidine |
|
Acute Myeloid LeukaemiaMDS - Myelodysplastic syndrome |
| BrECADD |
|
Advanced Stage Hodgkin Lymphoma |
| CEOP |
|
Non Hodgkin Lymphoma |
| CHOP |
|
Non Hodgkin Lymphoma |
| CODOX-M |
Inpatient Fluid balance (Same monitoring as high dose methotrexate) |
High-grade lymphomas: Burkitt's lymphoma DLBCL with adverse features |
| DA |
|
Acute Myeloid Leukaemia |
| DBLd |
|
Newly diagnosed multiple myeloma |
| Elranatamab |
|
BiTE therapy (Bispecific T-cell engager) for Myeloma |
| Epcoritamab |
|
BiTE therapy (Bispecific T-cell engager) for Lymphoma |
| Escalated BEACOPDac |
|
Advanced stage Hodgkin Lymphoma where escalated therapy is indicated |
| FLAG-IDA |
|
Acute Myeloid Leukaemia |
| GD-Carbo |
|
Lymphoma |
| GDP |
|
Curative or salvage treatment before autologous stem cell transplant |
| High dose methotrexate |
|
Acute Lymphoblastic Leukaemia, High Grade Lymphomas, Prophylaxis and treatment of CNS Lymphoma |
| IVAC |
|
High Grade Lymphoma |
| IVE |
|
Lymphoma |
| LEAM |
|
Autologous Transplant conditioning for Lymphoma |
| Len/Dex |
|
Multiple Myeloma |
| MATRIX |
|
CNS Lymphoma |
| Obinutuzumab and Bendamustine |
High risk of reaction. Patient to be given pre meds |
Follicular Lymphoma |
| Obinutuzumab and Venetoclax |
|
Chronic Lymphocytic Leukaemia |
| R (Pre fix) Ritux |
High risk of reaction. Patient to be given pre meds |
When Rituximab is added to a regime it gets added as a pre fix e.g. R-CHOP |
| Venetoclax and Azacitidine |
|
Acute Myeloid Leukaemia |
| Zometa |
Pre treatment dental assessment required |
Myeloma |